Question

A client is receiving low–molecular-weight heparin to prevent thromboembolic complications. The nursing student asks the instructor the reason why this treatment is given instead of heparin. What is the instructor's best explanation of the rationale for LMWH over heparin?

Answer 1

Answer:

LMWH is associated with less thrombocytopenia than standard heparin. It requires less subcutaneous dosing when compared to heparin

Explanation:

Low-molecular-weight heparin is a type of the anticoagulant medications.

They are used in prevention of the blood clots and the treatment of the venous thromboembolism as well as in treatment of the myocardial infarction.

The difference between Heparin and LMWH is shown below.

• The average molecular weight of the heparin is about 15 kDa and that of  LMWH is about 4.5 kDa.
• LMWH requires less and frequent subcutaneous dosing as compared to heparin for the postoperative prophylaxis of the venous thromboembolism.
• LMWH requires no need for the monitoring of  APTT coagulation parameter  which is required for the high dose heparin.